Cell and Gene Outsourcing

31. Solving Aseptic Filling Challenges For Your Advanced Therapeutics 8/20/2025

    Explore aseptic filling workcells, modalities, agency approvals, and insights from six expert users that offer a peer-driven look at industry innovation and benchmarks.

32. The Continuation Of A Journey 8/19/2025

    One family managed to combine resources and people to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

33. Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids 8/14/2025

    Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

34. Regulatory Strategy And Submission Support 8/13/2025

    This Regulatory Operations Team enables biotech and pharmaceutical companies to focus on innovation while ensuring a smooth, compliant path to market entry.

35. Regulatory Strategy And Submission Support 8/13/2025

    Eliminate delays and ensure seamless regulatory alignment with an experienced toxicology services team.

36. Accelerate Your Drug Development With A Global Partner 8/13/2025

    With the right Chemistry, Manufacturing & Controls (CMC) consulting services, your organization can excel in early-stage strategizing, accelerate timelines, optimize processes, and reduce costs.

37. Advancing Oncology Innovation With Adaptive Trial Designs 8/12/2025

    When a biopharmaceutical company developing a novel therapy for solid tumor cancers became concerned with rapid over-enrollment from within a single region, they employed a CRO for assistance.

38. AAV Gene Therapy: Charting The Course Through Clinical Challenges 8/11/2025

    Clinical holds in AAV gene therapy often stem from CMC and quality issues. Learn about testing services that help developers navigate regulatory hurdles and accelerate therapeutic progress.

39. July 2025 — CDMO Opportunities And Threats Report 8/11/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

40. Expand Your Capabilities And Shorten Your Time-To-Clinic 8/7/2025

    Gain expert insights into cell line development for biologics commercialization. and learn how CLD services—from DNA to GMP Master Cell Bank—can accelerate your path to clinical success.